2905. Long-term Immunological Persistence of the Adjuvanted Recombinant Zoster Vaccine: Clinical Data and Mathematical Modeling

BACKGROUND: The adjuvanted recombinant zoster vaccine (RZV, GSK), administered to adults ≥ 50 years of age (YOA) demonstrated ≥ 90% efficacy against herpes zoster across all age cohorts. Vaccine-specific immune responses elicited by two RZV doses in adults ≥ 60 YOA have been shown to persist above p...

Descripción completa

Detalles Bibliográficos
Autores principales: Bastidas, Adriana, Catteau, Grégory, Volpe, Stéphanie, Mrkvan, Tomas, Enemuo, Adaora, Smetana, Jan, Schwarz, Tino, Rombo, Lars, Pauksens, Karlis, Berengier, Estelle, Hervé, Caroline, Oostvogels, Lidia, Schuind, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808880/
http://dx.doi.org/10.1093/ofid/ofz359.183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808880/
http://dx.doi.org/10.1093/ofid/ofz359.183

Ejemplares similares